Browsing "1. College of Medicine (의과대학)" by Identifier : 0340-7004

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:
  • Sort by:
  • In order:
  • Results/Page
  • Authors/Record:

Showing results 1 to 16 of 16

This table browses all dspace content
Issue DateTitleJournal Title
2006An intracellular antibody can suppress tumorigenicity in Hepatitis B virus X-expressing cellsCANCER IMMUNOLOGY IMMUNOTHERAPY
2009Anti-cancer activity and mechanistic features of a NK cell activating moleculeCANCER IMMUNOLOGY IMMUNOTHERAPY
2022Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial CANCER IMMUNOLOGY IMMUNOTHERAPY
2023CD20/TNFR1 dual-targeting antibody enhances lysosome rupture-mediated cell death in B cell lymphomaCANCER IMMUNOLOGY IMMUNOTHERAPY
1996Cellular resistance to the antimelanoma immunotoxin ZME-gelonin and strategies to target resistant cellsCANCER IMMUNOLOGY IMMUNOTHERAPY
2004Characteristics of the killing mechanism of human natural killer cells against hepatocellular carcinoma cell lines HepG2 and Hep3BCANCER IMMUNOLOGY IMMUNOTHERAPY
2019Distinct immunological properties of the two histological subtypes of adenocarcinoma of the ampulla of VaterCANCER IMMUNOLOGY IMMUNOTHERAPY
2023Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma CANCER IMMUNOLOGY IMMUNOTHERAPY
2023Dynamic changes in peripheral blood monocytes early after anti-PD-1 therapy predict clinical outcomes in hepatocellular carcinoma CANCER IMMUNOLOGY IMMUNOTHERAPY
2001Effect of interferon-γ on the susceptibility to Fas (CD95/APO-1)-mediated cell death in human hepatoma cellsCANCER IMMUNOLOGY IMMUNOTHERAPY
2022Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experienceCANCER IMMUNOLOGY IMMUNOTHERAPY
2020Factors associated with ocular adverse event after immune checkpoint inhibitor treatmentCANCER IMMUNOLOGY IMMUNOTHERAPY
2023Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing CANCER IMMUNOLOGY IMMUNOTHERAPY
2014Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancerCANCER IMMUNOLOGY IMMUNOTHERAPY
2009Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatmentCANCER IMMUNOLOGY IMMUNOTHERAPY
2020Tumor Immune Microenvironment in Cancer Patients With LeukocytosisCANCER IMMUNOLOGY IMMUNOTHERAPY
1

Browse

Links